Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2005

View Archived Issues

Potential oxazolidine candidate for the treatment of diabetes

CKD-712 is a promising agent for the treatment of sepsis

Clinical data suggests perifosine may be effective in sarcoma

Enzo Biochem receives grant to conduct study of EGS-21 for fatty liver disease

HIV compound SPD-754 licensed to Avexa

Recordati acquires Merckle's branded pharmaceutical business in Germany

Additional phase III Ceplene study in AML required by FDA

Taxus Liberte paclitaxel-eluting coronary stent launched in 18 countries

Sumitomo to transfer Calsed sales to Nippon Kayaku

GSK and Galapagos enter asthma target discovery alliance

Intercell to move IC-51 vaccine against Japanese encephalitis virus into phase III

Phase IIa Tetrodin study completes enrollment

Pharmexa inlicenses Antigenics' QS-21 adjuvant

Mycograb compassionate use program

Zoniporide reported to induce protective effects after resuscitation from ventricular fibrillation

Pivotal phase III study of Bio-E-Gel completes enrollment

Recombinant influenza vaccine with simplified delivery tested in humans

Endpoint not met in phase IIb study of Fibrostat for hypertrophic scars

TAK-242 shows promise in the treatment of sepsis

sNDA submitted for Xyrem

TB4 to be studied in phase II trial for venous stasis ulcers

Antitumor effects found for MLN-518 in cells expressing different KIT mutations

Phase Ib/II trial of Exherin cleared to begin by Swiss Medic

Bosentan shows efficacy in the prevention of digital ulcers associated with scleroderma

New antibacterial oxazolidinones from Orchid

GFAT inhibitors for type 2 diabetes disclosed in patent

Cytovia reports protease inhibitors coronaviruses and SARS-CoV

JNK inhibitors for neurodegenerative disorders in early development at Eisai

GSK prepares and tests novel compounds for proliferative diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...